Online Dermatology Prescription Platforms Compared

With AI-assisted teledermatology that requires clinician sign-off, a licensed clinician reviews the AI’s output before any prescription is issued. That is different from an algorithm recommending skin products without a prescriber reviewing the case, and it does not necessarily mean a physician provides the review.

Why online dermatology prescription platforms are not interchangeable

Someone seeking online care for acne or rosacea for the first time may find several services that appear to offer the same thing. Upload photos, answer a short questionnaire, and receive a prescription at a pharmacy. The process looks simple from the outside. Yet those steps reveal little about who will assess the skin concern, which treatments they can prescribe, or whether they will help if the first treatment does not work.

A service with a narrow range of prescriptions and no structured follow-up offers a different care relationship from one that can adjust treatment over time. Patients need to compare how well each care model fits their needs as well as how easy it is to get started.

Who actually reviews your case and what credentials they hold

Patients should first ask who reviews the individual case and what training and licensure that person holds. “Medical professionals” and “licensed providers” do not answer it fully. Platforms may use board-certified dermatologists, general practitioners, internists, nurse practitioners, or physician assistants. These are not interchangeable credentials, even when the clinicians have prescribing authority. The reviewer’s credentials are particularly important when a skin problem is difficult to identify from photographs.

Board-certified dermatologists complete medical school, a one-year preliminary internship, and a three-year dermatology residency, totaling four years of post-medical-school training. Their specialty training includes distinguishing conditions that can look similar in photos, such as rosacea, perioral dermatitis, and seborrheic dermatitis. A licensed general practitioner or internist may treat straightforward acne but does not have that specialty training and may be less prepared to assess skin problems that are hard to identify. Not every concern requires a dermatologist’s expertise. A complex history, prior treatment failure, or an atypical presentation gives that expertise greater weight.

Nurse practitioners and physician assistants have prescribing authority in most U.S. states, but state law sets what they can do and how they must be supervised. Their role should be clear before signup, rather than hidden behind a generic description of the care team. AI adds a separate question to this comparison. “AI-assisted” describes a workflow. The distinction is whether a licensed clinician reviews the AI’s output before prescribing, rather than leaving the individual assessment to an algorithm that recommends products.

For someone specifically seeking physician approval, licensed-clinician sign-off alone is not a complete answer. The reviewer’s credential still needs to be established. An algorithmic product recommendation without review by a licensed prescriber is not a prescription in the legal sense.

What the asynchronous care model means for prescription decisions

Credentials explain who makes the decision, but the review format shapes what that person can know. On almost all online dermatology platforms, the patient submits photos and a questionnaire for a clinician to review later. There is no real-time conversation in that initial exchange. This separates the patient’s submission from the clinician’s assessment and removes the need for both people to be available at once.

For most everyday skin questions, telehealth is a reasonable first step. Patients who have no local dermatologist can get specialty-level review without having to travel or set an appointment time. Clinicians can also review submissions at a time that allows focused attention without the rush of an in-office slot. These are genuine strengths of the model. Convenience here is not merely a shorter signup process, but a way to reduce geographic and scheduling barriers to care.

However, the clinician can work only with what the patient submits. Photo quality, complete answers, and a clear account of prior treatments all shape the available clinical picture. A missing piece of history can leave uncertainty. So can a skin concern for which texture, a border, or a lymph node examination would change the diagnosis. Specialty training helps interpret the evidence, but it cannot supply a physical examination that has not happened.

That limit makes the referral pathway part of the comparison. Most legitimate platforms include a way to decline to prescribe and direct patients to in-person care when the submission is insufficient. A refusal to prescribe is not necessarily a service failure. A clinician’s refusal to prescribe can be an appropriate response to the limits of photographs and written answers, even when the service has done its job.

Which conditions and prescriptions platforms will and will not handle

Even when a skin concern can be reviewed this way, it may fall outside the conditions the platform treats. Some services focus narrowly on acne and anti-aging, while others cover rosacea, eczema, hyperpigmentation, hair loss, and infections. Scope is not uniform across the category. A broad promise of “skin care” does not establish whether a particular concern falls within the service’s prescribing remit.

Many platforms address comedonal, inflammatory, and hormonal acne, as well as rosacea, hyperpigmentation, and melasma. Mild to moderate eczema, also called atopic dermatitis, and androgenetic alopecia, a form of hair loss, are also common areas of care. Other presentations require a different route. Suspicious lesions needing biopsy or in-person dermoscopy can be triaged online but cannot be definitively managed remotely. Psoriasis with systemic involvement requiring biologics is handled by some platforms but not others, and any presentation that cannot be diagnosed confidently from photos may fall outside online treatment.

Within a supported condition, the next question is what can actually be prescribed. A formulary is the range of medicines available through the service. A fixed formulary offering a single tretinoin concentration in one vehicle leaves less room to respond when a patient tolerates that formulation poorly. An open formulary allows the clinician to tailor strength, formulation, and combinations.

Some platforms use compounding pharmacy partnerships to provide customized formulations, such as tretinoin, niacinamide, and azelaic acid combined in one cream. That approach can be clinically useful. It also adds a quality-control variable through the compounding supply chain that calls for inquiry and an individual assessment of the approach. Available prescription options should be assessed for their fit with the patient.

How follow-up and treatment adjustment work across different platform models

Prescription flexibility becomes useful only if there is a way to revisit the treatment decision. What happens if the cream causes irritation, the treatment has not worked after eight weeks, or a new question arises? The first prescription does not answer those questions.

Some subscriptions include scheduled check-ins that ask patients to send updates for a clinician to review. This is the closest model to a continuous care relationship. Other platforms offer on-demand messaging, so patients can contact a clinician or care team but must start each exchange themselves. A third model has no structured follow-up, ending the engagement after the prescription unless the patient purchases again.

That distinction has clinical consequences because many dermatology treatments require adjustment over months. Tretinoin, topical antibiotics, and azelaic acid may need changes as treatment progresses, with tretinoin specifically requiring titration according to tolerance. A platform without a follow-up mechanism cannot safely support that process. Access to a care team also leaves open whether the original prescriber will review how treatment is going. Continuity includes both an opportunity to raise concerns and clarity about who takes responsibility for the next decision.

Some platforms use AI-assisted monitoring to compare photos taken over time and track how the skin responds to treatment. It can be valuable when a licensed clinician reviews the AI’s comparison, rather than leaving interpretation entirely to an algorithm. Initial sign-off is only part of that relationship. The practical question before subscribing is, “If my skin gets worse or I have a reaction, who do I contact, how quickly will they respond, and are they the same clinician who prescribed?” The answer reveals more about ongoing care than a general promise of AI-supported treatment.

How platforms price their services and what patients are actually paying for

The follow-up model also affects what a patient is buying. A monthly or quarterly subscription may cover consultations and follow-ups while leaving medications to be paid for separately, either at a pharmacy or through the platform. A per-consultation service may charge for the first review and then charge again for later care. The headline prices are not directly comparable. One may represent access over time, while another represents a single clinical decision.

Bundled fees cover both a consultation and a fixed product shipment. These can be harder to interpret because the cost of clinical review is embedded in the product margin. A message-based consultation that charges a flat fee for each clinical interaction makes it clear how much the review costs. That can be especially clear for patients seeking occasional, as-needed access without a subscription commitment. It separates one identifiable service from the rest of the bill.

A consultation fee may exclude prescriptions, and a customized compound may cost substantially more than a generic equivalent because of compounding pharmacy markups. Insurance is another separate question. Coverage for the clinical consultation is rare in this category, though some platforms accept it. A clear price description distinguishes these charges instead of leaving the patient to discover them after signing up.

Auto-renewal and cancellation policies can lead to unexpected costs after a treatment course ends. For a fair comparison, the patient needs the consultation charge, medication cost, follow-up charges, and any subscription commitment in view together. A flat, disclosed consultation fee is easier to budget for than a bundle of services whose individual value is unclear, but transparency depends on knowing what remains outside that fee.

A practical framework for evaluating any online derm platform before you sign up

A useful evaluation begins with four questions about the care behind the interface. Who prescribes, what can be prescribed, how does follow-up work, and what is the total cost? Each needs a concrete answer before signup. For clinician credentials, that means asking for the reviewer’s training and licensure rather than accepting “licensed provider” as sufficient, particularly after treatment failure or with a complex concern. Where AI is involved, it also means asking whether clinician review is mandatory before prescribing and whether that clinician is a physician if physician oversight is the goal.

Patients should check both whether the service treats their condition and whether it can adjust treatment. A service may support acne yet have limited alternatives if the first formulation is poorly tolerated. Look for a structured check-in mechanism, establish whether the original prescriber reviews progress, and ask how concerns receive a response. To compare the full cost of that care, patients need to count medicines and repeat consultations, check whether they can use insurance, and read the cancellation terms.

The weight given to each answer depends on the concern. Someone with mild acne or known, stable rosacea has more flexibility than someone whose condition is ambiguous, treatment-resistant, or changing. In those cases, patients need to give more weight to clinician credentials and how follow-up works. A changing or suspicious lesion needs an in-person evaluation first, regardless of how an online platform is organized. For everyday concerns suited to telehealth, understanding these differences lets the patient choose a care model deliberately rather than defaulting to whichever service appears first in search results.